May 18, 2024

In WSJ Crisis of the Week, Poor Communications Earns Juno an “Incomplete”

Juno PhotoIn tests of its leukemia-fighting drug, Juno Therapeutics, Inc., botched the handling of patient deaths — and even how many, Judy Phair observes.  Incomplete information, dribbled out as the crisis unfolded, put the firm on the defense.  It’s the latest the in Wall Street Journal’s Risk & Compliance Journal.